CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
OV101 (gaboxadol)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03697161
NCT03697161Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome

Healx AI·interventional·Posted Oct 5, 2018·Updated Jan 23, 2024

In Brief

A Phase 2 clinical trial evaluating OV101 (gaboxadol) for Fragile X Syndrome (FXS). Completed, enrolled 36 participants across 6 sites.

Detailed Summary

The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101 (gaboxadol) in subjects with Fragile X syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFragile X Syndrome (FXS)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 5, 2018
Enrollment StartSep 17, 2018
Primary CompletionFeb 3, 2020
Study CompletionFeb 26, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.7 years ago

Interventions

OV101 (gaboxadol)drug

OV101 (gaboxadol)